Which is better, HRMY or TAK?

On the Buffett-Fit framework, Harmony Biosciences Holdings, Inc. (HRMY) currently grades higher than TAK — 67/100 (B grade) vs 44/100 (D). That said, "better" depends on which framework you trust — HRMY wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Charlie Munger, and Terry Smith; TAK wins on Joel Greenblatt. The full pillar breakdown is on this page.

Should I buy HRMY or TAK?

This page is an educational comparison, not investment advice. Both HRMY and TAK are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is HRMY better than TAK for value investing?

On the Buffett-style value-investing framework, HRMY currently grades higher — 67/100 vs 44/100, a 23-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between HRMY and TAK on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). HRMY currently scores 67/100 (B grade); TAK scores 44/100 (D grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, HRMY or TAK?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. HRMY and TAK are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, HRMY or TAK?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are HRMY and TAK both Healthcare stocks?

Yes — both Harmony Biosciences Holdings, Inc. (HRMY) and Takeda Pharmaceutical Company Limited (TAK) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this HRMY vs TAK comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Harmony Biosciences Holdings

Takeda Pharmaceutical Company Limited

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

HRMY

Market cap

$1.75B

Sector

Healthcare

TAK

Takeda Pharmaceutical Company Limited

Market cap

$51.34B

Sector

Healthcare

Overall winner

Harmony Biosciences Holdings HRMY

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	HRMY	TAK	Winner
Warren Buffett	67B	44D	HRMY
Benjamin Graham	60C	56C	HRMY
Philip Fisher	75B	40D	HRMY
Peter Lynch	62C	18F	HRMY
Joel Greenblatt	28F	32F	TAK
Charlie Munger	62C	41D	HRMY
Terry Smith	67B	36D	HRMY

Side-by-side metrics

Metric	HRMY	TAK
Market cap	$1.75B	$51.34B
P/E (TTM)	11.8x	43.0x
EV/EBIT	6.4x	22.0x
ROIC (TTM)	12.5%	2.59%
Gross margin	76.55%	58.76%
Net margin	16.2%	4.26%
Revenue CAGR 5y	29.85%	7.56%
EPS CAGR 5y	46.45%	-3.46%
Debt / Equity	0.2x	0.6x
Dividend yield	0.0%	3.79%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

HRMY leads on

EPS CAGR 5y46.45%vs -3.46%+107%
ROIC (TTM)12.5%vs 2.59%+79%
Revenue CAGR 5y29.85%vs 7.56%+75%
Net margin16.2%vs 4.26%+74%

TAK leads on

Dividend yield3.79%vs 0.0%+100%
Market cap$51.34Bvs $1.75B+97%

More like HRMY

HRMY vs HALO HRMY vs LMAT HRMY vs RMD HRMY vs LLY HRMY vs UTHR HRMY vs HAE

More like TAK

TAK vs HALO TAK vs LMAT TAK vs RMD TAK vs LLY TAK vs UTHR TAK vs HAE

Read the full Buffett-Brain analysis for HRMY Read the full Buffett-Brain analysis for TAK

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Harmony Biosciences Holdings

Takeda Pharmaceutical Company Limited

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

HRMY

Harmony Biosciences Holdings

Market cap

$1.75B

Sector

Healthcare

TAK

Takeda Pharmaceutical Company Limited

Market cap

$51.34B

Sector

Healthcare

Overall winner

Harmony Biosciences Holdings HRMY

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	HRMY	TAK	Winner
Warren Buffett	67B	44D	HRMY
Benjamin Graham	60C	56C	HRMY
Philip Fisher	75B	40D	HRMY
Peter Lynch	62C	18F	HRMY
Joel Greenblatt	28F	32F	TAK
Charlie Munger	62C	41D	HRMY
Terry Smith	67B	36D	HRMY

Side-by-side metrics

Metric	HRMY	TAK
Market cap	$1.75B	$51.34B
P/E (TTM)	11.8x	43.0x
EV/EBIT	6.4x	22.0x
ROIC (TTM)	12.5%	2.59%
Gross margin	76.55%	58.76%
Net margin	16.2%	4.26%
Revenue CAGR 5y	29.85%	7.56%
EPS CAGR 5y	46.45%	-3.46%
Debt / Equity	0.2x	0.6x
Dividend yield	0.0%	3.79%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

HRMY leads on

EPS CAGR 5y46.45%vs -3.46%+107%
ROIC (TTM)12.5%vs 2.59%+79%
Revenue CAGR 5y29.85%vs 7.56%+75%
Net margin16.2%vs 4.26%+74%

TAK leads on

Dividend yield3.79%vs 0.0%+100%
Market cap$51.34Bvs $1.75B+97%

More like HRMY

HRMY vs HALO HRMY vs LMAT HRMY vs RMD HRMY vs LLY HRMY vs UTHR HRMY vs HAE

More like TAK

TAK vs HALO TAK vs LMAT TAK vs RMD TAK vs LLY TAK vs UTHR TAK vs HAE

Read the full Buffett-Brain analysis for HRMY Read the full Buffett-Brain analysis for TAK

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.